Thus, patients with AR-positive tumor had a significantly lower risk of BC recurrence (5-year actuarial recurrence-free survival: 73% v 57%; P = 0.031, Figure 2A), compared with those with AR-negative tumor. The gene discussed is AR; the disease is breast cancer.